X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (315) 315
rosuvastatin calcium (293) 293
male (236) 236
fluorobenzenes - pharmacokinetics (225) 225
index medicus (207) 207
pharmacology & pharmacy (193) 193
animals (170) 170
rosuvastatin (153) 153
sulfonamides - pharmacokinetics (143) 143
pyrimidines - pharmacokinetics (141) 141
female (135) 135
pharmacokinetics (119) 119
adult (112) 112
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (111) 111
fluorobenzenes - therapeutic use (102) 102
middle aged (99) 99
fluorobenzenes - pharmacology (92) 92
rats (92) 92
fluorobenzenes - administration & dosage (88) 88
sulfonamides - therapeutic use (83) 83
pyrimidines - therapeutic use (82) 82
statins (79) 79
atorvastatin (77) 77
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (72) 72
pyrimidines - administration & dosage (72) 72
sulfonamides - administration & dosage (71) 71
fluorobenzenes - blood (69) 69
drug interactions (67) 67
fluorobenzenes - adverse effects (61) 61
aged (59) 59
pravastatin (59) 59
sulfonamides - pharmacology (58) 58
sulfonamides - blood (57) 57
pyrimidines - blood (56) 56
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (54) 54
pyrimidines - pharmacology (54) 54
simvastatin (54) 54
area under curve (52) 52
dose-response relationship, drug (52) 52
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (51) 51
sulfonamides - adverse effects (51) 51
pyrimidines - adverse effects (50) 50
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (47) 47
mice (44) 44
hypercholesterolemia - drug therapy (41) 41
treatment outcome (41) 41
atorvastatin calcium (39) 39
rats, sprague-dawley (39) 39
administration, oral (37) 37
cholesterol, ldl - blood (37) 37
fluorobenzenes - metabolism (37) 37
young adult (37) 37
hydroxymethylglutaryl-coa reductase inhibitors - blood (36) 36
cross-over studies (35) 35
sulfonamides (35) 35
organic anion transporters - metabolism (33) 33
time factors (33) 33
pyrimidines (32) 32
toxicology (32) 32
density-lipoprotein cholesterol (31) 31
fluorobenzenes - chemistry (31) 31
tissue distribution (31) 31
piperidines - pharmacokinetics (30) 30
cholesterol (29) 29
liver - metabolism (29) 29
safety (29) 29
clinical trials as topic (28) 28
efficacy (28) 28
metabolism (28) 28
adolescent (27) 27
cardiac & cardiovascular systems (27) 27
chemistry, analytical (27) 27
hypercholesterolemia (27) 27
organic anion transporters - genetics (27) 27
reproducibility of results (27) 27
antilipemic agents (26) 26
biochemistry & molecular biology (26) 26
coronary-heart-disease (26) 26
double-blind method (26) 26
fluorobenzenes (26) 26
lipids (26) 26
solute carrier organic anion transporter family member 1b1 (26) 26
healthy-volunteers (25) 25
hepatocytes - metabolism (25) 25
medicine, general & internal (25) 25
adult male-volunteers (24) 24
drug therapy, combination (24) 24
kinetics (24) 24
medicine, research & experimental (24) 24
analysis (23) 23
risk factors (23) 23
atp binding cassette transporter, sub-family g, member 2 (22) 22
brain - metabolism (22) 22
chromatography, high pressure liquid (22) 22
dogs (22) 22
dosage and administration (22) 22
pyrimidines - metabolism (22) 22
sulfonamides - metabolism (22) 22
anticholesteremic agents - therapeutic use (21) 21
hepatic-uptake (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (412) 412
Russian (4) 4
Chinese (2) 2
French (2) 2
Japanese (2) 2
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Pharmaceutics, ISSN 1543-8384, 08/2012, Volume 9, Issue 8, pp. 2358 - 2363
The aims of this work were to study pharmacokinetics of randomly selected drugs in plasma and saliva samples in healthy human volunteers, and to introduce a... 
Salivary Excretion Classification System | effective permeability | pharmacokinetics | protein binding | bioequivalence | SimCYP | MEDICINE, RESEARCH & EXPERIMENTAL | RELATIVE BIOAVAILABILITY | PERMEABILITY | CLINICAL PHARMACOKINETICS | BIOLOGICAL FLUID | DRUGS | PHARMACOLOGY & PHARMACY | Quinolines - blood | Acetates - blood | Fluorobenzenes - pharmacokinetics | Hydrochlorothiazide - pharmacokinetics | Triazoles - blood | Piroxicam - blood | Azithromycin - blood | Humans | Losartan - blood | Saliva - secretion | Male | Naphthalenes - blood | Benzhydryl Compounds - blood | Fluorobenzenes - pharmacology | Quinolines - pharmacokinetics | Sulfonamides - blood | Azithromycin - pharmacokinetics | Tolterodine Tartrate | Female | Triazoles - pharmacokinetics | Naphthalenes - pharmacokinetics | Piroxicam - analogs & derivatives | Sitagliptin Phosphate | Hydrochlorothiazide - blood | Losartan - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Metformin - blood | Cresols - blood | Phenylpropanolamine - blood | Metformin - pharmacokinetics | Rosuvastatin Calcium | Cloxacillin - pharmacokinetics | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Cinacalcet Hydrochloride | Cloxacillin - blood | Saliva - metabolism | Pyrazines - pharmacokinetics | Piroxicam - pharmacokinetics | Pyrimidines - pharmacokinetics | Cresols - pharmacokinetics | Anthraquinones - blood | Anthraquinones - pharmacokinetics | Phenylpropanolamine - pharmacokinetics | Pyrazines - blood | Acetates - pharmacokinetics
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2014, Volume 54, Issue 6, pp. 649 - 656
Statins are commonly used medications by HIV‐1 patients. Elvitegravir/cobicistat/emtricitabine/tenofovir DF is a single tablet regimen for the treatment of... 
pharmacokinetics | organic anion transporting polypeptide | breast cancer resistance protein | Stribild | statins | elvitegravir | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Anti-HIV Agents - pharmacology | Fluorobenzenes - pharmacokinetics | Organic Anion Transporters, Sodium-Independent - antagonists & inhibitors | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Neoplasm Proteins - antagonists & inhibitors | Carbamates - pharmacokinetics | Fluorobenzenes - pharmacology | Drug Interactions | Organic Anion Transporters, Sodium-Independent - metabolism | Quinolones - pharmacokinetics | Madin Darby Canine Kidney Cells | Solute Carrier Organic Anion Transporter Family Member 1B3 | Carbamates - pharmacology | Organic Anion Transporters - antagonists & inhibitors | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Cobicistat | ATP-Binding Cassette Transporters - antagonists & inhibitors | Thiazoles - blood | Cricetulus | Quinolones - pharmacology | Neoplasm Proteins - metabolism | Organic Anion Transporters - metabolism | Thiazoles - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Quinolones - blood | Sulfonamides - blood | ATP-Binding Cassette Transporters - metabolism | Adult | Female | Anti-HIV Agents - blood | Drug Therapy, Combination | Fluorobenzenes - blood | CHO Cells | Carbamates - blood | Animals | Anti-HIV Agents - pharmacokinetics | Dogs | Thiazoles - pharmacology | Drug Combinations | Rosuvastatin | Dosage and administration | Pharmacokinetics | Analysis | Confidence intervals | Rodents
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 12/2007, Volume 82, Issue 6, pp. 726 - 733
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1... 
COA REDUCTASE INHIBITOR | ANION TRANSPORTING POLYPEPTIDE | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | HEALTHY-VOLUNTEERS | INDUCED MYOPATHY | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | CLINICAL-RELEVANCE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Area Under Curve | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Administration, Oral | Pyrimidines - administration & dosage | Liver - metabolism | Rosuvastatin Calcium | Genotype | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Heptanoic Acids - blood | Sulfonamides - administration & dosage
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 168 - 176
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/ Slco1a4 , in drug transport across the blood-brain barrier. In vitro... 
LOCALIZATION | INVOLVEMENT | POLYPEPTIDE-2 | PENETRATION | PHARMACOLOGY & PHARMACY | RAT-BRAIN | OATP2 | BCRP/ABCG2 | 17-BETA-ESTRADIOL-D-17-BETA-GLUCURONIDE | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Fluorobenzenes - pharmacokinetics | Gene Expression - genetics | Pyrimidines - blood | Humans | Ion Pumps - genetics | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Pyrimidines - metabolism | Brain - metabolism | Quinolines - pharmacokinetics | Choroid Plexus - blood supply | ATP-Binding Cassette Transporters - genetics | Ochratoxins - administration & dosage | Cell Membrane - metabolism | Cerebral Cortex - drug effects | Capillaries - metabolism | Fluorobenzenes - metabolism | Tetrahydroisoquinolines - pharmacology | Organic Cation Transport Proteins - metabolism | Pravastatin - metabolism | Liver - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Taurocholic Acid - administration & dosage | Pravastatin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - administration & dosage | Pyrimidines - pharmacokinetics | Mice | Kinetics | Organic Cation Transport Proteins - genetics | Pravastatin - pharmacokinetics | Sulfonamides - administration & dosage | Quinolines - blood | Digoxin - metabolism | Taurocholic Acid - metabolism | Choroid Plexus - metabolism | Taurocholic Acid - blood | Ochratoxins - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Ochratoxins - metabolism | Cerebral Cortex - metabolism | Organic Anion Transporters - metabolism | Brain - blood supply | Sulfonamides - blood | Organic Anion Transporters - genetics | Transfection | Fluorobenzenes - blood | Enkephalin, D-Penicillamine (2,5)- - pharmacokinetics | Recombinant Proteins - metabolism | Cell Line | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Recombinant Proteins - genetics | Blood-Brain Barrier - drug effects | Digoxin - pharmacokinetics | Quinolines - metabolism | Taurocholic Acid - pharmacokinetics | Liver - blood supply | Pharmaceutical Preparations - metabolism | Animals | Digoxin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - metabolism | Acridines - pharmacology | Sulfonamides - metabolism
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 02/2010, Volume 10, Issue 1, pp. 1 - 11
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of... 
SLCO1B1 | Statin | Transporter | Cholesterol | Myopathy | Polymorphism | REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | myopathy | DRUG-INTERACTIONS | MULTIPLE-DOSE PRAVASTATIN | polymorphism | C SLC21A6 | LIPID-LOWERING EFFICACY | ANION TRANSPORTING POLYPEPTIDE | ABCB1 HAPLOTYPES | statin | transporter | GENETICS & HEREDITY | FUNCTIONAL-ANALYSIS | cholesterol | PHARMACOLOGY & PHARMACY | SINGLE NUCLEOTIDE POLYMORPHISMS | Haplotypes | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Liver | Hepatocytes - metabolism | Hypercholesterolemia - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pharmacogenetics | Gene Frequency | Rosuvastatin Calcium | Simvastatin - pharmacokinetics | Anticholesteremic Agents - adverse effects | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Asian Continental Ancestry Group | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | HeLa Cells | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Research | Health aspects | Coronary heart disease | Genetic polymorphisms | Statins | Risk factors
Journal Article
Xenobiotica, ISSN 0049-8254, 10/2013, Volume 43, Issue 10, pp. 920 - 931
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2004, Volume 75, Issue 5, pp. 455 - 463
Journal Article
Journal Article
Transplantation, ISSN 0041-1337, 06/2014, Volume 97, Issue 12, pp. 1266 - 1271
BACKGROUNDDyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR... 
Renal transplantation | Lipid lowering | Rosuvastatin | Drug-drug interaction | Everolimus | Pharmacokinetic | SURGERY | MANAGEMENT | IMMUNOLOGY | ATORVASTATIN | TRANSPLANTATION | GLOMERULAR-FILTRATION-RATE | IN-VITRO | PHARMACOKINETICS | DISEASE | HEALTHY-VOLUNTEERS | DYSLIPIDEMIA | INHIBITORS | CYCLOSPORINE | Fluorobenzenes - pharmacokinetics | Prospective Studies | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Drug Interactions | Fatty Acids, Monounsaturated - therapeutic use | Cytochrome P-450 CYP3A - genetics | Fatty Acids, Monounsaturated - adverse effects | Lipids - blood | Female | Dyslipidemias - etiology | Sirolimus - adverse effects | Dyslipidemias - drug therapy | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Rosuvastatin Calcium | Genotype | Treatment Outcome | Sirolimus - pharmacokinetics | Biomarkers - blood | Sulfonamides - pharmacokinetics | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Cytochrome P-450 CYP3A - metabolism | Norway | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Fatty Acids, Monounsaturated - pharmacokinetics | Immunosuppressive Agents - adverse effects | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Fluorobenzenes - adverse effects | Drug Substitution | Fluorobenzenes - therapeutic use | Kidney Transplantation - adverse effects
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2014, Volume 54, Issue 10, pp. 1144 - 1152
Journal Article